por
Jara, Alejandro,
Undurraga, Eduardo A,
Zubizarreta, José R,
González, Cecilia,
Pizarro, Alejandra,
Acevedo, Johanna,
Leo, Katherinne,
Paredes, Fabio,
Bralic, Tomás,
Vergara, Verónica,
Mosso, Marcelo,
Leon, Francisco,
Parot, Ignacio,
Leighton, Paulina,
Suárez, Pamela,
Rios, Juan Carlos,
García-Escorza, Heriberto,
Araos, Rafael
Publicado 2022
“…METHODS: Using individual-level data, we evaluated a prospective, observational, national-level cohort of individuals (aged ≥16 years) affiliated with the
Fondo Nacional de Salud insurance programme in
Chile, to assess the effectiveness of CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), or BNT162b2 (Pfizer-BioNTech) vaccine boosters in individuals who had completed a primary immunisation schedule with CoronaVac, compared with unvaccinated individuals. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online
Artículo
Texto
